Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

Proceedings of the Japan Academy Series B: Physical and Biological Sciences

Volumn 90, Issue 3, 2014, Pages 104-117

  Kaneko, Naoki ^a   Yamamoto, Rie ^a   Sato, Taka Aki ^a   Tanaka, Koichi ^a  

^a SHIMADZU CORPORATION   (Japan)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Amyloid ; Immunoprecipitation; Matrix assisted laser desorption ionization time of flight mass spectrometry; Plasma

Indexed keywords

AMYLOID BETA PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BLOOD; BLOOD ANALYSIS; CHEMISTRY; HUMAN; IMMUNOPRECIPITATION; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; METHODOLOGY; MOLECULAR GENETICS; REPRODUCIBILITY;

AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; BLOOD CHEMICAL ANALYSIS; HUMANS; IMMUNOPRECIPITATION; MOLECULAR SEQUENCE DATA; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84896836139     PISSN: 03862208     EISSN: 13492896     Source Type: Journal    
DOI: 10.2183/pjab.90.104     Document Type: Article

References (41)

1. Blennow, K., de Leon, M.J. and Zetterberg, H. (2006) Alzheimer's disease. Lancet 368, 387-403.
2. Hardy, J.A. and Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
3. Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik, K.H., Multhaup, G., Beyreuther, K. and Müller-Hill, B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736.
4. Selkoe, D.J. (2004) Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 6, 1054-1061.
5. Gowing, E., Roher, A.E., Woods, A.S., Cotter, R.J., Chaney, M., Little, S.P. and Ball, M.J. (1994) Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J. Biol. Chem. 269, 10987- 10990.
6. Gandy, S., Zhang, Y., Ikin, A., Schmidt, S.D., Bogush, A., Levy, E., Sheffield, R., Nixon, R.A., Liao, F.-F., Mathews, P.M., Xu, H. and Ehrlich, M.E. (2007) Alzheimer's presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo. J. Neurochem. 102, 619-626.
7. Thinakaran, G. and Koo, E.H. (2008) Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615-29619.
8. Ginsberg, S.D., Alldred, M.J., Counts, S.E., Cataldo, A.M., Neve, R.L., Jiang, Y., Wuu, J., Chao, M.V., Mufson, E.J., Nixon, R.A. and Che, S. (2010) Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol. Psychiatry 68, 885-893.
9. Funk, K.E. and Kuret, J. (2012) Lysosomal fusion dysfunction as a unifying hypothesis for Alzheimer's disease pathology. Int. J. Alzheimers Dis. 2012, 752894.
10. Chesneau, V., Vekrellis, K., Rosner, M.R. and Selkoe, D.J. (2000) Purified recombinant insulindegrading enzyme degrades amyloid beta-protein but does not promote its oligomerization. Biochem. J. 351 (Pt 2), 509-516.
11. Mukherjee, A., Song, E., Kihiko-Ehmann, M., Goodman, J.P., Pyrek, J.S., Estus, S. and Hersh, L.B. (2000) Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J. Neurosci. 20, 8745-8749.
12. Iwata, N., Higuchi, M. and Saido, T.C. (2005) Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol. Ther. 108, 129-148.
13. Andreasson, U., Portelius, E., Andersson, M.E., Blennow, K. and Zetterberg, H. (2007) Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomark. Med. 1, 59-78.
14. Hansson, O., Zetterberg, H., Buchhave, P., Andreasson, U., Londos, E., Minthon, L. and Blennow, K. (2007) Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23, 316-320.
15. Gustafson, D.R., Skoog, I., Rosengren, L., Zetterberg, H. and Blennow, K. (2007) Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J. Neurol. Neurosurg. Psychiatry 78, 461-464.
16. Herukka, S.-K., Helisalmi, S., Hallikainen, M., Tervo, S., Soininen, H. and Pirttilä, T. (2007) CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol. Aging 28, 507-514.
17. Hampel, H., Shen, Y., Walsh, D.M., Aisen, P., Shaw, L.M., Zetterberg, H., Trojanowski, J.Q. and Blennow, K. (2010) Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp. Neurol. 223, 334-346.
18. Vigo-Pelfrey, C., Lee, D., Keim, P., Lieberburg, I. and Schenk, D.B. (1993) Characterization of betaamyloid peptide from human cerebrospinal fluid. J. Neurochem. 61, 1965-1968.
19. Wang, R., Sweeney, D., Gandy, S.E. and Sisodia, S.S. (1996) The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J. Biol. Chem. 271, 31894-31902.
20. Portelius, E., Westman-Brinkmalm, A., Zetterberg, H. and Blennow, K. (2006) Determination of betaamyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res. 5, 1010-1016.
21. Portelius, E., Tran, A.J., Andreasson, U., Persson, R., Brinkmalm, G., Zetterberg, H., Blennow, K. and Westman-Brinkmalm, A. (2007) Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome Res. 6, 4433-4439.
22. Portelius, E., Brinkmalm, G., Tran, A.J., Zetterberg, H., Westman-Brinkmalm, A. and Blennow, K. (2009) Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener. Dis. 6, 87-94.
23. Portelius, E., Dean, R.A., Gustavsson, M.K., Andreasson, U., Zetterberg, H., Siemers, E. and Blennow, K. (2010) A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res. Ther. 2, 7.
24. Huang, Y., Potter, R., Sigurdson, W., Kasten, T., Connors, R., Morris, J.C., Benzinger, T., Mintun, M., Ashwood, T., Ferm, M., Budd, S.L. and Bateman, R.J. (2012) O-Amyloid dynamics in human plasma. Arch. Neurol. 69, 1591-1597.
25. Dimeski, G. and Barnett, R.J. (2005) Effects of total plasma protein concentration on plasma sodium, potassium and chloride measurements by an indirect ion selective electrode measuring system. Crit. Care Resusc. 7, 12-15.
26. Hu, S., Loo, J.A. and Wong, D.T. (2006) Human body fluid proteome analysis. Proteomics 6, 6326- 6353.
27. Gelfanova, V., Higgs, R.E., Dean, R.A., Holtzman, D.M., Farlow, M.R., Siemers, E.R., Boodhoo, A., Qian, Y.-W., He, X., Jin, Z., Fisher, D.L., Cox, K.L. and Hale, J.E. (2007) Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief. Funct. Genomics Proteomics 6, 149-158.
28. Magparangalan, D.P., Garrett, T.J., Drexler, D.M. and Yost, R.A. (2010) Analysis of large peptides by MALDI using a linear quadrupole ion trap with mass range extension. Anal. Chem. 82, 930-934.
29. Rüfenacht, P., Güntert, A., Bohrmann, B., Ducret, A. and Döbeli, H. (2005) Quantification of the A beta peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. J. Mass Spectrom. 40, 193-201.
30. Brinkmalm, G., Portelius, E., Öhrfelt, A., Mattsson, N., Persson, R., Gustavsson, M.K., Vite, C.H., Gobom, J., Månsson, J.-E., Nilsson, J., Halim, A., Larson, G., Rüetschi, U., Zetterberg, H., Blennow, K. and Brinkmalm, A. (2012) An online nano-LCESI- FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid. J. Mass Spectrom. 47, 591- 603.
31. Al-Ayadhi, L.Y., Ben Bacha, A.G., Kotb, M. and El- Ansary, A.K. (2012) A novel study on amyloid O peptide 40, 42 and 40/42 ratio in Saudi autistics. Behav. Brain Funct. 8, 4.
32. Fukuyama, Y., Nakajima, C., Furuichi, K., Taniguchi, K., Kawabata, S.-I., Izumi, S. and Tanaka, K. (2013) Alkylated trihydroxyacetophenone as a MALDI matrix for hydrophobic peptides. Anal. Chem. 85, 9444-9448.
33. Murphy, M.P., Hickman, L.J., Eckman, C.B., Uljon, S.N., Wang, R. and Golde, T.E. (1999) gamma- Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length. J. Biol. Chem. 274, 11914-11923.
34. Beher, D., Wrigley, J.D.J., Owens, A.P. and Shearman, M.S. (2002) Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. J. Neurochem. 82, 563- 575.
35. Fluhrer, R., Multhaup, G., Schlicksupp, A., Okochi, M., Takeda, M., Lammich, S., Willem, M., Westmeyer, G., Bode, W., Walter, J. and Haass, C. (2003) Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. J. Biol. Chem. 278, 5531-5538.
36. Carson, J.A. and Turner, A.J. (2002) Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J. Neurochem. 81, 1-8.
37. Vassar, R. and Citron, M. (2000) Abeta-generating enzymes: recent advances in beta- and gammasecretase research. Neuron 27, 419-422.
38. Ida, N., Hartmann, T., Pantel, J., Schröder, J., Zerfass, R., Förstl, H., Sandbrink, R., Masters, C.L. and Beyreuther, K. (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271, 22908- 22914.
39. Irizarry, M.C. (2004) Biomarkers of Alzheimer disease in plasma. NeuroRx 1, 226-234.
40. Fukuyama, R., Mizuno, T., Mori, S., Nakajima, K., Fushiki, S. and Yanagisawa, K. (2000) Agedependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur. Neurol. 43, 155-160.
41. Hansson, O., Zetterberg, H., Buchhave, P., Andreasson, U., Londos, E., Minthon, L. and Blennow, K. (2007) Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23, 316-320.